KDM5A and acute myeloid leukemia: In addition, two particular NUP98 fusions, NUP98–lysine demethylase 5A (KDM5A, a.k.a. JARID1A, or RBP2) and NUP98–NSD1, are molecular hallmarks of cytogenetically silent infant or childhood AML, respectively.